Teaching an old dog new tricks: reactivated developmental signaling pathways regulate ABCB1 and chemoresistance in
Wing-Kee Lee1, Thévenod Frank1
1Institute for Physiology, Pathophysiology and Toxicology, ZBAF, Witten/Herdecke University, Witten 58453, Germany.
Abstract:
Oncogenic multidrug resistance (MDR) is a multifactorial phenotype intimately linked to deregulated expression of detoxification transporters. Drug efflux transporters, particularly the MDR P-glycoprotein ABCB1, represent a central mechanism by which not only chemotherapeutic drugs are extruded or sequestered to prevent drug delivery to their intracellular targets, but also for inhibiting apoptotic cell death cues, such as removal of proapoptotic signals. Several cell populations exhibiting the MDR phenotype co-exist within a tumor, such as cells forming the bulk tumor cell mass, cancer stem cells, and cancer persister cells. The key to regulation of ABCB1 expression is the cellular transcriptional machinery. Developmental signaling pathways (e.g, Hedgehog, Notch, Wnt/β-catenin, TGFβ, PITX2) are pivotal in governing cell proliferation, survival, differentiation and guiding cell migration during embryogenesis, and their reactivation during carcinogenesis, which is of particular significance for tumor initiation, progression, and metastasis, also leads to the upregulation of ABCB1. These pathways also drive and maintain cancer cell stemness, for which ABCB1 is used as a marker. In this review, the contribution of canonical and non-canonical developmental signaling pathways in transcriptional regulation of ABCB1 to confer MDR in cancer is delineated.
Insights
Developmental signaling pathways reactivated in cancer drive multidrug resistance (MDR) by upregulating the ABCB1 transporter. This impacts tumor progression, metastasis, and cancer stemness.
Area of Science:
- Oncology
- Molecular Biology
- Cell Biology
Background:
- Multidrug resistance (MDR) in cancer is linked to transporter expression.
- ABCB1 (P-glycoprotein) mediates drug efflux and inhibits apoptosis.
- Tumors contain diverse cell populations with MDR phenotypes.
Purpose of the Study:
- To review the role of developmental signaling pathways in ABCB1 transcriptional regulation.
- To explore how these pathways contribute to MDR in cancer.
Main Methods:
- Literature review focusing on developmental signaling pathways and ABCB1.
- Analysis of canonical and non-canonical pathway contributions to MDR.
Main Results:
- Developmental pathways (Hedgehog, Notch, Wnt, TGFβ, PITX2) are reactivated in cancer.
- These pathways transcriptionally upregulate ABCB1, conferring MDR.
- ABCB1 is implicated in cancer stemness and is a marker for it.
Conclusions:
- Canonical and non-canonical developmental signaling pathways are key regulators of ABCB1 expression in cancer.
- Understanding these pathways offers insights into overcoming MDR and targeting cancer stem cells.
Related Concept Videos
Treatment Resistant Cancers
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Targeted Cancer Therapies
There are several types of targeted therapies against...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Inhibition of Cdk Activity


